Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | L. T. Jennelle, Dissertation, 2013, George Washington University | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | C. T. Hellwig et al., J. Biol. Chem., Aug 2008; 283: 21676 - 21685 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Boudra et al., Cell Cycle, 2016, 15:10,1352-1362; DOI: 10.1080/15384101.2016.1166319 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | S. Roesch et al., Int. J. Mol. Sci., 2018, 19, 209 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | P. Aridon, Parkinsonism and Related Disorders, 2016, 31:135-138, doi.org/10.1016/j.parkreldis.2016.08.016 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Cohen et al., Biochim. et Biophysica Acta, 2013, 1833: 1104–1113, doi.org/10.1016/j.bbamcr.2012.12.021 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | J. Arias del Val, PhD Thesis, 2018, Universidad de Valladolid | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S. de la Fuente et al., Biochem. J., 2014, 458: 33-40, doi:10.1042/BJ20131025 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., J. Lipid Res., Nov 2008; 49: 2312 - 2322 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | J. Schulz et al., Scientific Reports, 2018, 8: 2395, DOI:10.1038/s41598-018-19201-8 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T. Sasazuki et al., J. Biol. Chem., Aug 2002; 277: 28853 - 28860 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. T. Hellwig et al., J. Cell Sci., May 2010; 123: 1401 - 1406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | publication | E. Roscioli et al., J. Cell Biol., Feb 2012; 196: 435 - 450 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | R. Costa., Front. Cell Dev. Biol., 2020, 8: 607080, doi: 10.3389/fcell.2020.607080 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. G. Theis et al., PNAS, Aug 2004; 101: 11221 - 11226 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | peptide | K2 Transfection System | publication | L. Iarriccio et al., PLOS ONE, 2015, DOI:10.1371/journal.pone.0142980 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. C. Mayer et al., J. Immunol., Oct 2013; 191: 3594 - 3604 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | V. De Leo et al., Toxicol. Res., 2017, 6: 947, DOI: 10.1039/c7tx00172 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Neumann-Giesen et al., J. Cell Sci., Feb 2007; 120: 395 - 406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | L. Jennelle et al., J. Biol. Chem., Oct 2014; 289: 28870 - 28884. | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | B. Blumenthal et al., Infect. Immun., Jul 2007; 75: 3344 - 3353 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S.Haering, Dissertation, 2016, Ruhr University Bochum | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | D.W. Chen et al., In: C. Boon, J. Wijnholds (eds) Retinal Gene Therapy. Methods in Molecular Biology, 2018, 1715, Humana Press, NY | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | V. Mikat et al., RNA, Dec 2007; 13: 2341 - 2347 | Link |